Author: Customer Service

The share repurchase programme runs as from 5 February 2026 and up to and including 29 January 2027 at the latest. In this period, Jyske Bank will acquire shares with a value of up to DKK 3 billion, cf. Corporate Announcement No. 11/2026 of 5 February 2026. The share repurchase programme is initiated and structured in compliance with the Market Abuse Regulation (Regulation (EU) No 596/2014) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (together with the Market Abuse Regulation, the “Safe Harbour Rules”). The following transactions have been made under the program:  Number of shares Average purchase price (DKK) Transaction value (DKK)Accumulated, previous announcement 1,411,357 909.62 1,283,805,1866 July 2026 11,121 972.90 10,819,5817 July 2026 11,626 980.80 11,402,7548 July 2026 11,659 969.99 11,309,0719...

Stellantis Reports Q2 2026 Estimated Consolidated Shipments of 1.6 Million Units, +10% Year-Over-YearNorth America Shipments Up 38%, Driven by New Product Launches; Enlarged Europe Also Reports GrowthAMSTERDAM, July 13, 2026 – Stellantis N.V. today released its Q2 2026 estimated consolidated shipments. The term “shipments” describes the volume of vehicles delivered to dealers, distributors, or directly from the Company to retail and fleet customers, which generally drive revenue recognition. Consolidated shipments for the three months ended June 30, 2026, were an estimated 1.6 million units, up 10% year-over-year. Growth was driven primarily by North America and Enlarged Europe, partially offset by lower volumes in the Middle East & Africa, largely due to the regional conflict, and in South America, where a weaker Argentine market...

Sampo plc, stock exchange release, 13 July 2026 at 8:30 am EEST Sampo plc’s share buybacks week 28/2026 During week 28 (6 July 2026 – 10 July 2026), Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI4000552500) as follows:Market (MIC Code) Daily volume (in number of shares) and weighted average price of the purchased shares, EUR* Aggregated weekly volume (in number of shares) and weighted weekly average price of the purchased shares, EUR*    06/07/2026 07/07/2026 08/07/2026 09/07/2026 10/07/2026 Week 28/2026, totalAQEU Volume 0 0 0 0 0 0Average price 0.00 0.00 0.00 0.00 0.00 0.00CEUX Volume 6,974 3,516 2,924 0 0 13,414Average price 9.29 9.30 9.42 0.00 0.00 9.32TQEX Volume 1,813 1,875 1,285 0 0 4,973Average price 9.28 9.29 9.40 0.00 0.00 9.31XHEL Volume 5,934 5,597 5,285 0 0 16,816Average...

La Hulpe, Belgium – July 13, 2026, 07:00 CEST – INSIDE INFORMATION – Banqup Group SA, (Euronext:BANQ) (Banqup, Company) announces that it has entered into an incremental facility notice under itsexisting Senior Facilities Agreement dated 7 March 2022 (as amended) with funds affiliated with FranciscoPartners, one of its existing senior secured lenders, for an additional committed term facility of EUR 4.0million (the Incremental Facility). Facility A under the Senior Facilities Agreement now stands at EUR 4,000,000, and the Incremental Facilityprovides the Company with additional financial flexibility to support the Group’s liquidity position pendingcompletion of the strategic review process announced by the Company. The Company’s Board of Directors has also approved the possibility of further incremental facilities of up to...

Pratteln, Switzerland, July 13, 2026 – Santhera Pharmaceuticals (SIX: SANN) today announces an expansion of its exclusive distribution agreement with Biomedica for AGAMREE® (vamorolone), extending the partnership to include Georgia, Kazakhstan, Belarus, Azerbaijan and Uzbekistan, for the treatment of Duchenne muscular dystrophy (DMD) in patients two years of age and older. Biomedica was originally appointed as a distributor for AGAMREE® in October 2025. Under the expanded agreement, Biomedica will be responsible for distribution in the additional five markets, while Santhera will continue to receive a percentage of net sales in line with the terms of the original agreement. Approximately 2,000 patients are living with DMD across these additional countries, where treatment options have historically been largely limited to standard corticosteroids....

Health Canada NOC enables treatment for porphyria, metabolic disorder MELBOURNE, Australia, July 13, 2026 (GLOBE NEWSWIRE) — CLINUVEL’s novel drug SCENESSE® (afamelanotide) has been granted a Notice of Compliance (NOC) by Health Canada for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The NOC acknowledges the compliance of the SCENESSE® new drug submission with Section C.08.002 and C.08.005 of the Canadian Food and Drug Regulations and grants CLINUVEL the right to market SCENESSE® in Canada. Commentary “Health Canada has taken a long time to arrive at this positive outcome,” said Dr Dennis Wright, CLINUVEL’s Chief Scientific Officer. “Data from our global programs – including considerable data from postmarketing experience – were used to demonstrate the safety and clinical benefit of...

Common stock begins trading on the OTCQB under the symbol “PALX” effective July 10, 2026; Company continues development of its core optical technologies focused on moving data faster and more efficiently in AI data centers GOLETA, Calif., July 13, 2026 (GLOBE NEWSWIRE) — Palomino Laboratories, Inc. (OTCQB: PALX) (“Palomino” or the “Company”), an innovator in optical interconnect technologies designed to address the rapidly increasing bandwidth and energy-efficiency requirements of artificial intelligence (AI), high-performance computing (HPC), and next-generation data centers, today announced that its common stock has begun trading on the OTCQB Venture Market under the ticker symbol “PALX.” The Company’s shares are also DTC eligible, enabling electronic clearing and settlement...

HONOLULU, July 12, 2026 (GLOBE NEWSWIRE) — First Hawaiian, Inc. (NASDAQ: FHB) announced today that it plans to release its second quarter 2026 financial results on Friday, July 24, 2026 before the market opens. First Hawaiian will host a conference call to discuss the company’s results on the same day at 1:00 p.m. Eastern Time (7:00 a.m. Hawaii Time). To access the call by phone, participants will need to click on the following registration link: https://register-conf.media-server.com/register/BIb8e318d9b8d24417b3d7d113fcf80dbc, register for the conference call, and then you will receive the dial-in number and a personalized PIN code. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. A live webcast of the conference call, including a slide presentation,...

PERTH, Australia , July 12, 2026 (GLOBE NEWSWIRE) — Paladin Energy Ltd (ASX:PDN, TSX:PDN, OTCQX:PALAF) (“Paladin” or the “Company”) advises that it will release its quarterly results for the period ended 30 June 2026 on the ASX platform on Wednesday, 22 July 2026. The announcement will also be available on the SEDAR+ platform. The Company will hold a conference call on Wednesday, 22 July 2026, at 11.00am AEST1 (Tuesday, 21 July 2026, at 9.00pm EDT2). To participate in the live teleconference, please register at the link below: Paladin June 2026 Quarterly Results Conference Call Please note it is recommended to log on at least five minutes before the scheduled commencement time to ensure you are registered in time for the start of the call. A recording of the call will be available on Paladin’s website shortly after its conclusion. This...